Skip to main content
Equibles
MEDS logo

MEDS · DataMeds AI, Inc. · Metrics

Track MEDS — free

Use MEDS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MEDS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.87 -0.08 (-8.70%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Aug 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months from the date these unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 17, 2026
Market Cap
$2.66M
Shares
3.06M
Volume · Nov 12 155.41K Avg daily vol (3M) 6.43M

MEDS metrics

56 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.87
Market cap
$2.66M

Price action

23 metrics
Price change (1W)
-36.0%
Price change (30D)
-68.5%
Price change (3M)
-28.3%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
449.4%
Annualized volatility (3M)
591.4%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
-0.6
RSI (14D)
28.8
Price vs SMA 50
-61.6%
Price vs SMA 200
—
Avg volume (3M)
6.43M
Relative volume
0.0
Average dollar volume
$27.88M

Company

3 metrics
Sector
Healthcare
Industry
Medical Distribution
Shares outstanding
3.06M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4.0×
reciprocal yield 24.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.4×
reciprocal yield 274.9%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3,024.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.8×
reciprocal yield 35.5%
EV / revenue historical average (5Y)
2.8×
reciprocal yield 35.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
-90.6%
Operating margin
-875.7%
Trailing 12 months
Net margin
-1,100.3%
Gross profit (TTM)
−$7.27M
Operating profit (TTM)
−$70.26M
Net income (TTM)
−$88.28M
Trailing 12 months
Diluted EPS (TTM)
$-45.73
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-6.14

Growth

11 metrics
Revenue growth YoY
-77.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$8.02M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+108.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-269.5%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$67.94M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-11.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$29.35M
Latest balance sheet
Cash & equivalents
$2.46M
Total assets
$32.76M
Total debt
$31.81M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$13.74M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$28.65M
R&D / revenue
—
Stock compensation / revenue
357.1%

Ownership (13F)

9 metrics
13F filers
9
13F filer change QoQ
-4
Institutional ownership
1.7%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+255.4%
Holder tenure
2.8
Price vs estimated holder cost
-90.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.8%

Short interest

3 metrics
Short interest
12.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 2030763 CUSIP 949503205 13F (30d) 9 filings 9 filers Visit website Investor relations